MeSH D000077195 - squamous cell carcinoma of head and neck
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000077195:Â
Squamous cell carcinoma of head and neck
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Bristol Myers Squibb | Nivolumab | Opdivo |  | 2015-06-19 | $9,491 M | Q2/24-Q1/25 |
| Merck & Co | Pembrolizumab | Keytruda |  | 2015-07-17 | $29,740 M | Q2/24-Q1/25 |
Clinical Trials
Historical Success Rate
Phase 1
71%94/133
Phase 2
20%33/168
Phase 3
20%10/49
Approved: 2Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use